What question did this study set out to answer?

To evaluate the long-term clinical efficacy, tolerability, and overall survival of patients with intermediate-2 or high-risk myelofibrosis treated with ruxolitinib compared to matched historical controls.

June 21, 2012BloodOpen Access

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

View Full Paper

Ask AI

Bookmark

Authors

SVSrđan Verstovšek HKHagop M. Kantarjian ZEZeev Estrov

Discussion

Member takes

Overview

Clinical trial analysis reveals improved overall survival with ruxolitinib in myelofibrosis, suggesting a disease-modifying advantage over historical controls.

Key Points

To evaluate the long-term clinical efficacy, tolerability, and overall survival of patients with intermediate-2 or high-risk myelofibrosis treated with ruxolitinib compared to matched historical controls.
Analyzed 107 patients with intermediate-2 or high-risk myelofibrosis treated with ruxolitinib at MD Anderson Cancer Center in a phase 1/2 trial with a median follow-up of 32 months.
Compared overall survival against 310 matched historical control patients identified using the trial's enrollment criteria.
Overall survival was significantly superior in ruxolitinib-treated patients compared to 310 matched historical controls (P = .005), driven by a marked survival advantage in the high-risk subgroup (P = .006).
Treatment was maintained in 54% of patients at a median follow-up of 32 months, with cumulative discontinuation rates of 24% at 1 year, 36% at 2 years, and 46% at 3 years.
Patients achieving a ≥50% reduction in splenomegaly experienced significantly prolonged survival compared to those with a <25% reduction (P < .0001).

Cite This Study

Verstovšek et al. (2012) studied this question.

synapsesocial.com/papers/69dff21c2c052bbf722554c3 https://doi.org/10.1182/blood-2012-02-414631

View Full Paper

Ask AI

Bookmark

June 21, 2012BloodOpen Access

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

View Full Paper

Ask AI

Bookmark

Authors

SVSrđan Verstovšek HKHagop M. Kantarjian ZEZeev Estrov

Discussion

Member takes

Overview

Clinical trial analysis reveals improved overall survival with ruxolitinib in myelofibrosis, suggesting a disease-modifying advantage over historical controls.

Key Points

To evaluate the long-term clinical efficacy, tolerability, and overall survival of patients with intermediate-2 or high-risk myelofibrosis treated with ruxolitinib compared to matched historical controls.
Analyzed 107 patients with intermediate-2 or high-risk myelofibrosis treated with ruxolitinib at MD Anderson Cancer Center in a phase 1/2 trial with a median follow-up of 32 months.
Compared overall survival against 310 matched historical control patients identified using the trial's enrollment criteria.
Overall survival was significantly superior in ruxolitinib-treated patients compared to 310 matched historical controls (P = .005), driven by a marked survival advantage in the high-risk subgroup (P = .006).
Treatment was maintained in 54% of patients at a median follow-up of 32 months, with cumulative discontinuation rates of 24% at 1 year, 36% at 2 years, and 46% at 3 years.
Patients achieving a ≥50% reduction in splenomegaly experienced significantly prolonged survival compared to those with a <25% reduction (P < .0001).

Cite This Study

Verstovšek et al. (2012) studied this question.

synapsesocial.com/papers/69dff21c2c052bbf722554c3 https://doi.org/10.1182/blood-2012-02-414631

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark